V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008825 | 240005387 | null | 67.4 | Curative (C) | 2016-07-25 | 2016-08-05 | EC | N | null | 240024570 | BEVACIZUMAB + CARBO + DOCETAXEL |
| 240008826 | 240010960 | null | 56 | Neo-adjuvant (N) | 2015-01-12 | 2015-01-13 | Methotrexate intrathecal | Y | N | 240024640 | LENALIDOMIDE |
| 240008827 | 240005388 | 1.75 | 74.2 | Curative (C) | 2014-12-26 | 2015-01-03 | CAPECITABINE + RT | N | N | 240024680 | LENALIDOMIDE |
| 240008828 | 240005389 | null | 86 | Curative (C) | 2015-10-07 | 2015-10-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | 240024747 | CHOEP |
| 240008829 | 240005389 | null | null | null | 2017-12-20 | 2017-12-20 | Cisplatin +Fluorouracil (3 wk) | 99 | null | 240024747 | RUXOLITINIB |
| 240008830 | 240005390 | 1.67 | 65.8 | Curative (C) | 2013-08-31 | 2013-09-01 | Carboplatin + Liposomal Doxorubicin | 02 | N | 240025020 | PACLITAXEL |
| 240008831 | 240005391 | 1.58 | 43.6 | null | 2013-05-19 | 2013-05-19 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | N | N | 240025108 | CAPECITABINE + OXALIPLATIN |
| 240008832 | 240005392 | 1.69 | 79 | Palliative (P) | 2016-01-31 | 2016-01-31 | Cyclophosphamide + Dex + Rituximab | N | N | 240025111 | TRASTUZUMAB |
| 240008833 | 240005393 | 1.72 | 67 | Not known (9) | 2016-05-09 | 2016-05-24 | REMODLB TRIAL | N | N | 240025126 | IPILIMUMAB |
| 240008834 | 240005394 | 1.75 | 84.1 | Not known (9) | 2018-07-12 | 2018-07-28 | AML 18 TRIAL | null | N | 240025194 | PMITCEBO-R |
| 240008835 | 240005394 | 1.55 | 53.3 | Curative (C) | 2018-10-04 | 2018-11-01 | REMODLB TRIAL | 02 | N | 240025194 | GEMCITABINE |
| 240008836 | 240005395 | null | 64.7 | null | 2014-10-05 | 2015-12-10 | Capecitabine | 02 | N | 240025291 | R-EPOCH |
| 240008837 | 240010963 | 1.68 | 86 | Palliative (P) | 2017-05-17 | 2017-05-17 | Bevacizumab 15mg/kg | 1 | N | 240025324 | METHOTREXATE INTRATHECAL |
| 240008838 | 240005396 | 1.65 | 68.5 | Curative (C) | 2016-09-03 | 2016-09-08 | mEOC TRIAL | N | N | 240025383 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008839 | 240005397 | 1.78 | 86 | Palliative (P) | null | 2017-10-29 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 240025391 | CISPLATIN + FLUOROURACIL + RT |
| 240008840 | 240005397 | 1.58 | 64 | Palliative (P) | 2018-06-25 | 2018-07-16 | REMODLB TRIAL | N | N | 240025391 | CVP |
| 240008841 | 240005398 | 1.6 | 55.8 | Curative (C) | 2017-10-21 | 2017-10-21 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 240025437 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240008842 | 240005398 | 1.85 | 81.6 | Curative (C) | 2016-04-23 | 2016-04-26 | Lomustine | 2 | N | 240025437 | AML19 TRIAL |
| 240008843 | 240005399 | 1.61 | 62 | Palliative (P) | 2015-02-25 | 2015-03-16 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | N | null | 240025582 | CYTARABINE |
| 240008844 | 240005400 | 1.75 | 91.5 | null | 2016-10-17 | 2016-10-18 | VEDex | null | N | 240025641 | CVP |
| 240008845 | 240005401 | 1.45 | 77 | Palliative (P) | 2018-08-30 | 2018-09-29 | AML17 TRIAL | 1 | N | 240025778 | ABVD |
| 240008846 | 240005401 | 1.52 | 65.7 | Disease modification (D) | 2013-07-22 | 2013-08-12 | CISPLATIN + FLUOROURACIL + RT | 2 | N | 240025778 | MATRIX TRIAL |
| 240008847 | 240005402 | 1.58 | 61.5 | Curative (C) | 2018-03-16 | 2018-03-17 | PEMBROLIZUMAB | N | N | 240025905 | R-EPOCH |
| 240008848 | 240005403 | 1.58 | 65.2 | null | 2013-07-31 | 2013-08-13 | PACLITAXEL + TRASTUZUMAB | N | N | 240025958 | PILOT TRIAL |
| 240008849 | 240005403 | 1.48 | 92 | null | null | 2013-10-01 | MABCUTE TRIAL | null | null | 240025958 | ABVD |
| 240008850 | 240005403 | 0 | null | Curative (C) | 2014-06-01 | 2014-06-02 | PCV | N | null | 240025958 | BORTEZOMIB |
| 240008851 | 240014979 | 1.78 | 99.8 | Palliative (P) | 2016-10-17 | 2016-10-17 | INCA TRIAL | 02 | N | 240026165 | FCR |
| 240008852 | 240014979 | 1.7 | 80 | Palliative (P) | 2016-11-20 | 2016-12-12 | Carboplatin + Vinorelbine Oral | null | N | 240026165 | CVP |
| 240008853 | 240005404 | 1.73 | 63.8 | Curative (C) | 2015-01-23 | 2015-01-26 | R CODOX-M/ R IVAC | 2 | N | 240026558 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008854 | 240005405 | 1.62 | 65.7 | Palliative (P) | 2013-12-20 | 2013-12-24 | Cisplatin + Etoposide (3 day) | N | N | 240026776 | CHOP R + METHOTREXATE |
| 240008855 | 240005406 | 1.75 | 86.3 | Palliative (P) | 2013-08-18 | 2013-08-22 | ESHAP | 02 | null | 240026787 | CHOP-R + CYTARABINE HIGH DOSE |
| 240008856 | 240005406 | 1.76 | 66.6 | Adjuvant (A) | 2016-07-30 | 2016-08-07 | Cyclophosphamide oral | N | N | 240026787 | MATRIX TRIAL |
| 240008857 | 240005406 | 1.58 | 60 | Disease modification (D) | 2016-06-17 | 2016-06-21 | FCR Oral - Cycle 1 | 01 | N | 240026787 | AML17 TRIAL |
| 240008858 | 240005407 | 1.54 | 63.5 | Curative (C) | null | 2017-02-03 | Palbociclib | N | N | 240027000 | FLUOROURACIL + MITOMYCIN + RT |
| 240008859 | 240005407 | 1.6 | 54.7 | Adjuvant (A) | 2015-02-01 | 2015-02-02 | Ipilimumab | 2 | N | 240027000 | CVP |
| 240008860 | 240005407 | null | 66.7 | Curative (C) | 2019-08-15 | 2019-08-15 | mEOC TRIAL | 2 | N | 240027000 | ECX |
| 240008861 | 240005408 | 1.6 | 66.7 | Curative (C) | 2016-07-21 | 2016-12-08 | Cisplatin + Etoposide (3 day) | N | N | 240027348 | CISPLATIN + ETOPOSIDE |
| 240008862 | 240005409 | 1.7 | null | Palliative (P) | 2018-03-26 | 2018-03-26 | R CODOX-M/ R IVAC | N | N | 240027414 | OXALIPLATIN + MDG |
| 240008863 | 240005410 | 0 | null | Curative (C) | 2016-12-31 | 2017-01-02 | Cytarabine Intrathecal (any age) | 02 | N | 240027452 | INCA TRIAL |
| 240008864 | 240005411 | 0 | 80.9 | Curative (C) | 2016-03-07 | 2016-03-07 | FCR IV - Cycle 1 | N | N | 240027530 | CYCLO + RITUXIMAB + VINCRISTINE |
| 240008865 | 240005412 | null | 59 | Adjuvant (A) | 2018-07-13 | 2018-07-13 | CTD Attenuated (Thalidomide 50mg) | N | null | 240027620 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008866 | 240005413 | 1.68 | 64 | Palliative (P) | 2014-05-25 | 2014-06-01 | Bortezomib + CYCLOPHOSPHAMIDE | 2 | Y | 240027765 | PACLITAXEL + TRASTUZUMAB |
| 240008867 | 240005413 | 1.53 | 45.9 | Radical (R) | 2015-04-15 | 2015-04-28 | CVP | null | null | 240027765 | CISPLATIN + FLUOROURACIL |
| 240008868 | 240005413 | 1.55 | 63.9 | Palliative (P) | 2014-05-17 | 2014-06-01 | CISPLATIN + ETOPOSIDE | N | N | 240027765 | PILOT TRIAL |
| 240008869 | 240005413 | 1.62 | 69.4 | Palliative (P) | 2014-12-18 | 2014-12-28 | Methotrexate intrathecal | N | N | 240027765 | CISPLATIN + ETOPOSIDE |
| 240008870 | 240015670 | 1.64 | 62.8 | Curative (C) | 2015-04-24 | 2015-05-26 | Cytarabine HD + Methotrexate HD | N | N | 240027988 | CYTARABINE |
| 240008871 | 240005414 | 1.6 | 58.9 | Curative (C) | 2018-01-06 | 2018-01-06 | Bortezomib + Cyclophos + Dex | 02 | N | 240028005 | BEVACIZUMAB |
| 240008872 | 240010971 | null | 65.2 | Curative (C) | 2017-12-20 | 2018-01-11 | ABVD | null | N | 240028008 | FLAG |
| 240008873 | 240010971 | 1.7 | 50.4 | Neo-adjuvant (N) | 2013-11-04 | 2013-11-04 | FLAG + Idarubicin | N | N | 240028008 | CISPLATIN + FLUOROURACIL + RT |
| 240008874 | 240005415 | null | 67.4 | null | 2016-03-18 | 2016-04-19 | Cytarabine Low Dose | null | N | 240028056 | THALIDOMIDE |